Acute visual loss after ipilimumab treatment for metastatic melanoma.
about
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery.Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system
P2860
Acute visual loss after ipilimumab treatment for metastatic melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Acute visual loss after ipilimumab treatment for metastatic melanoma.
@en
type
label
Acute visual loss after ipilimumab treatment for metastatic melanoma.
@en
prefLabel
Acute visual loss after ipilimumab treatment for metastatic melanoma.
@en
P2093
P2860
P1476
Acute visual loss after ipilimumab treatment for metastatic melanoma.
@en
P2093
Julia Kharlip
Kelly Guld
Leslie A Fecher
Lynn M Schuchter
Madhura Tamhankar
Ryan D Walsh
Suzanne McGettigan
P2860
P2888
P356
10.1186/S40425-016-0170-9
P577
2016-10-18T00:00:00Z
P6179
1002378303